Kasey Leger

Dr. Kasey Leger is a pediatric oncologist at Seattle Children’s Hospital with expertise in the areas of hematologic malignancies and cancer therapy associated cardiotoxicity. Dr. Leger is a Scholar in Clinical Research of the Leukemia & Lymphoma Society. She leads the Children’s Oncology Group (COG) Myeloid Cardiotoxicity Working Group and the cardiac correlative studies embedded in the ongoing COG phase III randomized trial of CPX-351 in children with de novo acute myeloid leukemia (AML). This study aims to evaluate strategies of primary cardioprotection and inform the utility of sensitive echocardiographic measures of myocardial function and cardiac biomarkers in predicting global cardiac dysfunction. Additionally, Dr. Leger is the principal investigator of the Seattle Children’s Cardiotoxicity Cohort Study assessing novel blood and imaging based markers of cardiotoxicity. Dr. Leger’s overarching research goals are to reduce the toxicity of cancer therapy through primary cardioprotective interventions and identify validated risk predictors to guide secondary/ tertiary cardioprotection and ultimately contribute to long-term leukemia cure without the burden of life-threatening heart disease during survivorship.